Answers are grounded in this paper and cite their sources.
Introduction Euglycemic Ketoacidosis is a relatively uncommon disease typically seen in diabetic patients. It has become more common with the widespread use of SGLT-2 inhibitors. We describe the diagnosis and treatment of a non-diabetic patient with Becker Muscular Dystrophy with severe euglycemic ketoacidosis developed while taking dapagliflozin for heart failure. This case lends credence to the wisdom of a more judicious use of this new medication. Case description A 52-year-old man with a past history of Becker muscular dystrophy and systolic heart failure (Ejection fraction 30%) was admitted with a 2-day history of diarrhea, anorexia and decreased urine output. He was initially prescribed dapagliflozin 2 years prior. He presented acutely ill with tachypnea and tachycardia. Initial labs were consistent with high-anion gap metabolic acidosis. His initial creatinine was 1.1 with a baseline of 0.1. He was anuric on admission.He received empiric antibiotics and aggressive fluid resuscitation - with no corresponding improvement in his BP and no pulmonary crackles or hypoxia. In the ICU, he received further fluids and norepinephrine infusion. Additional labs returned at this time confirmed severe ketosis and HgbA1c 4.7%, as well as a normal BUN and normal lactate. He continued to receive fluids as his anion gap normalized and he was weaned from norepinephrine. His first urinalysis returned 12 hours after presentation showing 3+ ketones and 3+ glucose. He received an insulin infusion with scheduled supplemental dextrose once ketoacidosis was diagnosed. Daily urinalysis was obtained to monitor the presence of ketosis. Treatment was difficult because of hypoglycemia with insulin. Ultimately, after 10 days from his most recent dose of dapagliflozin, the patient had a series of two negative urinalyses for ketones, and the insulin infusion was able to be discontinued. At this point, his clinical condition improved. He was ultimately discharged home with discontinuation of dapagliflozin. Discussion This case illustrates one of the hallmark dangers of SGLT-2 inhibitors, namely euglycemic ketoacidosis. It emphasizes the need for appropriate patient selection and patient education regarding side effects. The treatment is supportive with careful use of an insulin infusion titrated to avoid hypoglycemia.
No takes yet. Share an insight, caveat, or question.
Ball et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: